Literature DB >> 28053146

Molecular identification of chromoblastomycosis clinical isolates in Guangdong.

Cindy Fransisca1, Ya He1, Zhiwen Chen1, Hongfang Liu1, Liyan Xi1.   

Abstract

Chromoblastomycosis is a chronic fungal infection of the skin and subcutaneous tissue. The most common etiologic agent encountered in Southern China is from the genus Fonsecaea. Fonsecaea species are often misidentified due to indistinct morphology features; furthermore, recent taxonomy revision was done on the fungi genus. Herein, a comprehensive evaluation with molecular sequencing data based on internal transcribed spacer (ITS) ribosomal DNA regions as molecular targets were implemented to 37 clinical isolates from chromoblastomycosis patients. Twenty strains that were formerly identified as Fonsecaea pedrosoi through morphological characteristic were verified to be either Fonsecaea nubica or Fonsecaea monophora, while 17 strains were appropriately identified as F. monophora. A phylogenetic method was further performed to establish the species delimitation. Our investigations validate that the clinical isolates from Guangdong consist of F. monophora and the recently found new species, F. nubica. In this study, F. pedrosoi has not been isolated from chromoblastomycosis patients in Guangdong, Southern China. Reevaluation of previous reports regarding F. pedrosoi as chromoblastomycosis etiologic agent in China is necessary for a comprehensive assessment of geographic distribution pattern of Fonsecaea species. This study is the first reported study presenting large samples of F. nubica domestic or abroad.
© The Author 2017. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Chromoblastomycosis; Fonsecaea monophora; Fonsecaea nubica, Fonsecaea pedrosoi; ITS rDNA; molecular identification; phylogenetic study

Mesh:

Substances:

Year:  2017        PMID: 28053146     DOI: 10.1093/mmy/myw140

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  4 in total

1.  [Long-pulsed 1064 nm Nd: YAG laser combined with terbinafine against chromoblastomycosis caused by Fonsecaea nubica and the effect of laser therapy in a Wistar rat model].

Authors:  Juan Luo; Peiying Feng; Yongxuan Hu; Yemei Yang; Sitong Zhou; Songgen Huang; Abdulla Jadad; Zemin Zhong; Yushi Zheng; Kangxing Liu; Yan Lu; Yanqing Hu; Xianyi Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-06-30

2.  Pathogenicity and Growth Conditions Modulate Fonsecaea Extracellular Vesicles' Ability to Interact With Macrophages.

Authors:  Lucas de Oliveira Las-Casas; Clara Luna Freitas Marina; Raffael Júnio Araújo de Castro; Luísa Coutinho Coelho; Sônia Nair Báo; G Sybren de Hoog; Vânia Aparecida Vicente; Larissa Fernandes; Anamelia Lorenzetti Bocca
Journal:  Front Cell Infect Microbiol       Date:  2022-06-09       Impact factor: 6.073

3.  The Diagnosis of Fungal Neglected Tropical Diseases (Fungal NTDs) and the Role of Investigation and Laboratory Tests: An Expert Consensus Report.

Authors:  Roderick Hay; David W Denning; Alexandro Bonifaz; Flavio Queiroz-Telles; Karlyn Beer; Beatriz Bustamante; Arunaloke Chakrabarti; Maria de Guadalupe Chavez-Lopez; Tom Chiller; Muriel Cornet; Roberto Estrada; Guadalupe Estrada-Chavez; Ahmed Fahal; Beatriz L Gomez; Ruoyu Li; Yesholata Mahabeer; Anisa Mosam; Lala Soavina Ramarozatovo; Mala Rakoto Andrianarivelo; Fahafahantsoa Rapelanoro Rabenja; Wendy van de Sande; Eduard E Zijlstra
Journal:  Trop Med Infect Dis       Date:  2019-09-24

4.  Molecular Characteristics of Regional Chromoblastomycosis in Guangdong, China: Epidemiological, Clinical, Antifungal Susceptibility, and Serum Cytokine Profiles of 45 Cases.

Authors:  Hongfang Liu; Jiufeng Sun; Minying Li; Wenying Cai; Yangxia Chen; Yinghui Liu; Huan Huang; Zhenmou Xie; Weiying Zeng; Liyan Xi
Journal:  Front Cell Infect Microbiol       Date:  2022-02-18       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.